The evolving science of apolipoprotein-L1 and kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 3, 2016, Pages 217-225

  Chen, Teresa K ^a   Estrella, Michelle M ^a   Parekh, Rulan S ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Apolipoprotein L1; Chronic kidney disease; End stage renal disease; Genes; Risk factor

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; GENETIC RISK; GENETIC VARIABILITY; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY GRAFT; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; GENETIC PREDISPOSITION; GENETICS; GLOMERULUS FILTRATION RATE; METABOLISM;

ANIMALS; APOLIPOPROTEINS; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; LIPOPROTEINS, HDL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84961967602     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000222     Document Type: Review

References (60)

1. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-845.
2. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40:1185-1192.
3. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128:345-350.
4. Foster MC, Coresh J, Fornage M, et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 2013; 24:1484-1491.
5. Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369:2183-2196.
6. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129-2137.
7. National Heart L, and Blood Institute, National Institutes of Health. Who Is at Risk for Sickle Cell Disease? [Internet] Bethesda [updated 2015 Jun 12; cited 2016 Jan 10]. Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk.
8. Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 2014; 21:426-433.
9. O'Seaghdha CM, Parekh RS, Hwang SJ, et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Human Mol Genet 2011; 20:2450-2456.
10. Divers J, Palmer ND, Lu L, et al. Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant 2014; 29:587-594.
11. Ma J, Divers J, Palmer ND, et al. Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation. Kidney Int 2015; 88:584-592.
12. Divers J, Nunez M, High KP, et al. JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 2013; 84:1207-1213.
13. Estrella MM, Li M, Tin A, et al. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis 2015; 60:646-652.
14. Tin A, Grams ME, Maruthur NM, et al. Hemostatic factors, APOL1 risk variants, and the risk of ESRD in the atherosclerosis risk in communities study. Clin J Am Soc Nephrol 2015; 10:784-790.
15. Freedman BI, Pastan SO, Israni AK, et al. APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Trans plantation 2016; 100:194-202.
16. Chen TK, Choi MJ, Kao WH, et al. Examination of potential modifiers of the association of APOL1 alleles with CKD progression. Clin J Am Soc Nephrol 2015; 10:2128-2135.
17. Peralta CA, Bibbins-Domingo K, Vittinghoff E, et al. APOL1 genotype and race differences in incident albuminuria and renal function decline. J Am Soc Nephrol 2015; doi: 10.1681/ASN.2015020124. [Epub ahead of print]
18. Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013; 83:114-120.
19. Lentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010; 363:724-732.
20. Muzaale AD, Massie AB, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. JAMA 2014; 311:579-586.
21. Cherikh WS, Young CJ, Kramer BF, et al. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am J Transplant 2011; 11:1650-1655.
22. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socio-economic factors. N Engl J Med 1992; 327:840-845.
23. Lee BT, Kumar V, Williams TA, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12:1924-1928.
24. Reeves-Daniel AM, DePalma JA, Bleyer AJ, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11:1025-1030.
25. Freedman BI, Julian BA, Pastan SO, et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant 2015; 15:1615-1622.
26. Kofman T, Audard V, Narjoz C, et al. APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Am J Kidney Dis 2014; 63:816-819.
27. Papeta N, Kiryluk K, Patel A, et al. APOL1 Variants Increase Risk for FSGS and HIVAN but Not IgA Nephropathy. J Am Soc Nephrol 2011; 22:1991-1996.
28. Kasembeli AN, Duarte R, Ramsay M, et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J Am Soc Nephrol 2015; 26:2882-2890.
29. D'Agati V, Suh JI, Carbone L, et al. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int 1989; 35:1358-1370.
30. Jotwani V, Shlipak MG, Scherzer R, et al. APOL1 genotype and glomerular and tubular kidney injury in women with HIV. Am J Kidney Dis 2015; 65:889-898.
31. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21:2809-2813.
32. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546.
33. Larsen CP, Beggs ML, Saeed M, Walker PD. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomer-ulopathy. J Am Soc Nephrol 2013; 24:722-725.
34. Freedman BI, Langefeld CD, Andringa KK, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014; 66:390-396.
35. Colares VS, Titan SM, Pereira Ada C, et al. MYH9 and APOL1 gene polymorphisms and the risk of CKD in patients with lupus nephritis from an admixture population. PLoS One 2014; 9:e87716.
36. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175-1184.
37. Ashley-Koch AE, Okocha EC, Garrett ME, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155:386-394.
38. Naik RP, Derebail VK, Grams ME, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014; 312:2115-2125.
39. Cattaneo D, Ruggenenti P, Baldelli S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 2009; 20:1404-1415.
40. Park HC, Yasuda K, Ratliff B, et al. Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted. Am J Physiol Renal Physiol 2010; 298:F357-F364.
41. Madhavan SM, O'Toole JF, Konieczkowski M, et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22:2119-2128.
42. Ma L, Shelness GS, Snipes JA, et al. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol 2015; 26:339-348.
43. Kopp JB, Winkler CA, Zhao X, et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J Am Soc Nephrol 2015; 26:1443-1448.
44. Larsen CP, Beggs ML, Saeed M, et al. Histopathologic findings associated with APOL1 risk variants in chronic kidney disease. Mod Pathol 2015; 28:95-102.
45. Sampson MG, Robertson CC, Martini S, et al. Integrative genomics identifies novel associations with APOL1 risk genotypes in black NEPTUNE subjects. J Am Soc Nephrol 2015; doi: 10.1681/ASN.2014111131. [Epub ahead of print]
46. Hoy WE, Hughson MD, Kopp JB, et al. APOL1 risk alleles are associated with exaggerated age-related changes in glomerular number and volume in African-Americana adults: an autopsy study. J Am Soc Nephrol 2015; 26:3179-3189.
47. Johnstone DB, Shegokar V, Nihalani D, et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One 2012; 7:e51546.
48. Nichols B, Jog P, Lee JH, et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int 2015; 87:332-342.
49. Zhaorigetu S, Wan G, Kaini R, et al. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008; 4:1079-1082.
50. Lan X, Jhaveri A, Cheng K, et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol 2014; 307:F326-F336.
51. Limou S, Dummer PD, Nelson GW, et al. APOL1 toxin, innate immunity, and kidney injury. Kidney Int 2015; 88:28-34.
52. Freedman BI, Langefeld CD, Murea M, et al. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant 2011; 26:3805-3810.
53. Gutierrez OM, Judd SE, Irvin MR, et al. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. Nephrol Dial Transplant 2015; doi: 10.1093/ndt/gfv229. [Epub ahead of print]
54. Bentley AR, Divers J, Shriner D, et al. APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans. BMC Genomics 2015; 16:421.
55. Ruchi R, Genovese G, Lee J, et al. Copynumber variation atthe APOL1 locus. PLoS One 2015; 10:e0125410.
56. Ito K, Bick AG, Flannick J, et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 2014; 114:845-850.
57. Langefeld CD, Divers J, Pajewski NM, et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int 2015; 87:169-175.
58. Freedman BI, Langefeld CD, Lu L, et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int 2015; 87:176-181.
59. Tamrat R, Peralta CA, Tajuddin SM, et al. Apolipoprotein L1, income and early kidney damage. BMC Nephrol 2015; 16:14.
60. Atta MG, Estrella MM, Kuperman M, et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 2012; 82:338-343.